Sight Sciences, Inc. (SGHT)
NASDAQ: SGHT · Real-Time Price · USD
8.28
-0.11 (-1.31%)
Nov 28, 2025, 1:00 PM EST - Market closed
Sight Sciences Revenue
Sight Sciences had revenue of $19.91M in the quarter ending September 30, 2025, a decrease of -1.25%. This brings the company's revenue in the last twelve months to $76.05M, down -4.39% year-over-year. In the year 2024, Sight Sciences had annual revenue of $79.87M, down -1.47%.
Revenue (ttm)
$76.05M
Revenue Growth
-4.39%
P/S Ratio
5.67
Revenue / Employee
$352,093
Employees
216
Market Cap
442.01M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 79.87M | -1.19M | -1.47% |
| Dec 31, 2023 | 81.06M | 9.73M | 13.63% |
| Dec 31, 2022 | 71.33M | 22.38M | 45.70% |
| Dec 31, 2021 | 48.96M | 21.32M | 77.12% |
| Dec 31, 2020 | 27.64M | 4.29M | 18.38% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
SGHT News
- 23 days ago - Sight Sciences, Inc. (SGHT) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 24 days ago - Sight Sciences Reports Third Quarter 2025 Financial Results and Raises Full Year 2025 Revenue Guidance - GlobeNewsWire
- 24 days ago - Sight Sciences Appoints Ali Bauerlein as Chief Operating Officer and Jim Rodberg as Chief Financial Officer - GlobeNewsWire
- 26 days ago - Sight Sciences to Present at Two Upcoming Investor Conferences - GlobeNewsWire
- 5 weeks ago - Sight Sciences to Report Third Quarter 2025 Financial Results on November 6, 2025 - GlobeNewsWire
- 6 weeks ago - Sight Sciences Announces Fee Schedule Establishment from Novitas Solutions and First Coast Service Options for the TearCare® Interventional Dry Eye Procedure - GlobeNewsWire
- 2 months ago - Sight Sciences Announces Publication of a Systematic Literature Review and Meta-Analysis Showing OMNI® Surgical System Achieves Clinically Significant, Long-Term Reductions in IOP and Medication Use - GlobeNewsWire
- 2 months ago - Sight Sciences, Inc. (SGHT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript) - Seeking Alpha